Merit Medical Systems, Inc. (NASDAQ:MMSI) Director F. Ann Millner Sells 12,500 Shares

Merit Medical Systems, Inc. (NASDAQ:MMSI) Director F. Ann Millner sold 12,500 shares of the business’s stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $101.55, for a total transaction of $1,269,375.00. Following the sale, the director now owns 32,391 shares of the company’s stock, valued at $3,289,306.05. This trade represents a 27.85 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Merit Medical Systems Trading Up 2.0 %

MMSI traded up $1.99 during mid-day trading on Monday, reaching $103.82. The stock had a trading volume of 276,271 shares, compared to its average volume of 440,376. Merit Medical Systems, Inc. has a 52 week low of $65.46 and a 52 week high of $105.46. The company has a debt-to-equity ratio of 0.57, a quick ratio of 3.82 and a current ratio of 5.36. The stock has a market capitalization of $6.05 billion, a P/E ratio of 49.92, a P/E/G ratio of 2.53 and a beta of 0.89. The firm’s fifty day simple moving average is $97.80 and its two-hundred day simple moving average is $90.09.

Merit Medical Systems (NASDAQ:MMSI) last released its earnings results on Wednesday, October 30th. The medical instruments supplier reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.80 by $0.06. Merit Medical Systems had a return on equity of 15.61% and a net margin of 9.05%. The business had revenue of $339.85 million for the quarter, compared to the consensus estimate of $334.60 million. During the same quarter in the previous year, the business earned $0.75 earnings per share. Merit Medical Systems’s quarterly revenue was up 7.8% on a year-over-year basis. On average, equities analysts predict that Merit Medical Systems, Inc. will post 3.36 EPS for the current year.

Hedge Funds Weigh In On Merit Medical Systems

Institutional investors and hedge funds have recently made changes to their positions in the stock. American Century Companies Inc. increased its stake in shares of Merit Medical Systems by 2.9% during the 2nd quarter. American Century Companies Inc. now owns 4,216 shares of the medical instruments supplier’s stock worth $362,000 after purchasing an additional 118 shares during the last quarter. Xponance Inc. grew its holdings in shares of Merit Medical Systems by 4.9% during the second quarter. Xponance Inc. now owns 3,621 shares of the medical instruments supplier’s stock valued at $311,000 after buying an additional 170 shares during the last quarter. Glenmede Trust Co. NA grew its holdings in shares of Merit Medical Systems by 0.6% during the third quarter. Glenmede Trust Co. NA now owns 28,637 shares of the medical instruments supplier’s stock valued at $2,830,000 after buying an additional 170 shares during the last quarter. Captrust Financial Advisors boosted its holdings in Merit Medical Systems by 2.6% in the third quarter. Captrust Financial Advisors now owns 7,440 shares of the medical instruments supplier’s stock worth $735,000 after purchasing an additional 187 shares during the last quarter. Finally, Hancock Whitney Corp boosted its holdings in Merit Medical Systems by 2.7% in the third quarter. Hancock Whitney Corp now owns 8,122 shares of the medical instruments supplier’s stock worth $803,000 after purchasing an additional 214 shares during the last quarter. Institutional investors own 99.66% of the company’s stock.

Analysts Set New Price Targets

MMSI has been the topic of a number of research analyst reports. Piper Sandler restated an “overweight” rating and issued a $110.00 price target (up from $100.00) on shares of Merit Medical Systems in a report on Monday, September 9th. Wells Fargo & Company lifted their price target on Merit Medical Systems from $85.00 to $103.00 and gave the stock an “equal weight” rating in a report on Monday, September 16th. Bank of America lifted their target price on Merit Medical Systems from $92.00 to $103.00 and gave the company a “neutral” rating in a research report on Monday, September 16th. Robert W. Baird upped their price target on Merit Medical Systems from $107.00 to $109.00 and gave the company an “outperform” rating in a report on Thursday, October 31st. Finally, StockNews.com cut Merit Medical Systems from a “buy” rating to a “hold” rating in a research note on Sunday, November 3rd. Three research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Merit Medical Systems presently has an average rating of “Moderate Buy” and a consensus target price of $103.36.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.